FDA approves new treatment for those with advanced pancreatic cancer

Aug. 26 (UPI) — On Wednesday, the U.S. Food and Drug Administration announced its approval of Rasonque, a new treatment option for people with advanced pancreatic cancer.

A tablet taken once a day, the medication targets forms of a protein called RAS, which is a key driver of tumor growth in many patients with pancreatic adenocarcinoma, the most common form of the cancer, the FDA said. This form of cancer develops in cells lining the ducts of the pancreas.

“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer,” said Kyle Diamantas, acting commissioner of the FDA. “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible.”

A press release from the FDA said the approval demonstrates the agency’s “commitment to moving with urgency, reducing unnecessary delays and advancing innovative treatments.”

Rasonque has been approved for adults who have metastatic pancreatic adenocarcinoma who have received at one least one prior systemic therapy or those who are not candidates for multiagent systemic therapy.

About 90% to 95% of the new cases of pancreatic cancer diagnosed in the United States each year are this form, the FDA said, citing the National Cancer Institute. Johns Hopkins Medicine also said “the vast majority” of pancreatic cancer diagnoses are this form.

In a clinical trial, the new treatment improved median overall survival to 13.2 months from 6.7 months with standard chemotherapy, the FDA said.

“This drug showed unprecedented results in an area of high unmet need,” said Angelo de Claro, director of the FDA’s Oncology Center of Excellence.

The agency granted this approval to Revolution Medicines Inc.